Return to homepagePandemic Pact

Pilot, open, randomized clinical trial of combined use of Hydroxychloroquine, Azithromycin and Tocilizumab for the treatment of SARS-CoV-2 (COVID-19) infection

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00070

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Pere Domingo Pedrol

  • Research Location

    Spain

  • Lead Research Institution

    Fundacio Privada Institut de Recerca de LÇîHospital de la Santa Creu i Sant Pa

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The main objective of the study is to evaluate in-hospital mortality, need for mechanical ventilation, or need for rescue doses of tocilizumab in patients with confirmed COVID-19 infection receiving hydroxychloroquine and azithromycin combined with hocilizumab. The study will compare 2 branches, usual therapy in clinical practice, control branch; vs. tocilizumab treatment, experimental branch.